Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers

Cancer Research

Volumn 63, Issue 16, 2003, Pages 4920-4926

  Andrechek, Eran R ^a   Laing, Michael A ^a   Girgis Gabardo, Adele A ^a   Siegel, Peter M ^b   Cardiff, Robert D ^c   Muller, William J ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RNA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; GENE OVEREXPRESSION; HISTOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENIC MOUSE; TUMOR MODEL;

ANIMALS; BREAST NEOPLASMS; CARRIER PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENES, ERBB-2; GRB7 ADAPTOR PROTEIN; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS); PROTEINS;

EID: 0041438459     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Bargmann, C. I., Hung, M. C., and Weinberg, R. A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature, 319: 226-230, 1986.
2. Coussens, L., Yang-Feng, T. L., Liao, Y. C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Wash. DC), 230: 1132-1139, 1985.
3. Dougall, W. C., Qian, X., Peterson, N. C., Miller, M. J., Samanta, A., and Greene, M. I. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene, 9: 2109-2123, 1994.
4. Hynes, N. E., and Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta, 1198: 165-184, 1994.
5. Schechter, A. L., Stern, D. F., Vaidyanathan, L., Decker, S. J., Drebin, J. A., Greene, M. I., and Weinberg, R. A. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature, 312: 513-516, 1984.
6. Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidemioid carcinoma cells. Nature, 309: 418-425, 1984.
7. Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., and Aaronson, S. A. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA, 86: 9193-9197, 1989.
8. Plowman, G. D., Culouscou, J. M., Whitney, G. S., Green, J. M., Carlton, G. W., Foy, L., Neubauer, M. G., and Shoyab, M. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA, 90: 1746-1750, 1993.
9. Andrulis, I. L., Bull, S. B., Blackstein, M. E., Sutherland, D., Mak, C., Sidlofsky, S., Pritzker, K. P., Hartwick, R. W., Hanna, W., Lickley, L., et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J. Clin. Oncol., 16: 1340-1349, 1998.
10. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987.
11. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244; 707-712, 1989.
12. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., and Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 54: 105-115, 1988.
13. Guy, C. T., Cardiff, R. D., and Muller, W. J. Activated neu induces rapid tumor progression. J. Biol. Chem., 271: 7673-7678, 1996.
14. Bouchard, L., Lamarre, L., Tremblay, P. J., and Jolicoeur, P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell, 57: 931-936, 1989.
15. Siegel, P. M., Dankort, D. L., Hardy, W. R., and Muller, W. J. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol., 14: 7068-7077, 1994.
16. Siegel, P. M., Ryan, E. D., Cardiff, R. D., and Muller, W. J. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J., 18: 2149-2164, 1999.
17. Andrechek, E. R., Hardy, W. R., Siegel, P. M., Rudnicki, M. A., Cardiff, R. D., and Muller, W. J. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc. Natl. Acad. Sci. USA, 97: 3444-3449, 2000.
18. Montagna, C., Andrechek, E. R., Padilla-Nash, H., Muller, W. J., and Ried, T. Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene, 21: 890-898, 2002.
19. Bieche, I., Champeme, M. H., Matifas, F., Cropp, C. S., Callahan, R., and Lidereau, R. Two distinct regions involved in lp deletion in human primary breast cancer. Cancer Res., 53: 1990-1994, 1993.
20. Stein, D., Wu, J., Fuqua, S. A., Roonprapunt, C., Yajnik, V., D'Eustachio, P., Moskow, J. J., Buchberg, A. M., Osborne, C. K., and Margolis, B. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J., 13: 1331-1340, 1994.
21. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry, 18: 5294-5299, 1979.
22. Rauh, M. J., Blackmore, V., Andrechek, E. R., Tortorice, C. G., Daly, R., Lai, V. K., Pawson, T., Cardiff, R. D., Siegel, P. M., and Muller, W. J. Accelerated mammary tumor development in mutant polyomavirus middle T transgenic mice expressing elevated levels of either the Shc or Grb2 adapter protein. Mol. Cell. Biol., 19: 8169-8179, 1999.
23. Morrison, B. W., and Leder, P. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene, 9: 3417-3426, 1994.
24. Chiang, S. Y., Burli, R. W., Benz, C. C., Gawron, L., Scott, G. K., Dervan, P. B., and Beerman, T. A. Targeting the ets binding site of the HER2/ neu promoter with pyrrole-imidazole polyamides. J. Biol. Chem., 275: 24246-24254, 2000.
25. Xing, X., Wang, S. C., Xia, W., Zou, Y., Shao, R., Kwong, K. Y., Yu, Z., Zhang, S., Miller, S., Huang, L., et al. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat. Med., 6: 189-195, 2000.
26. Baert, J. L., Monte, D., Musgrove, E. A., Albagli, O., Sutherland, R. L., and de Launoit, Y. Expression of the PEA3 group of ETS-related transcription factors in human breast-cancer cells. Int. J. Cancer, 70: 590-597, 1997.
27. Shepherd, T. G., Kockeritz, L., Szrajber, M. R., Muller, W. J., and Hassell, J. A. The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr. Biol., 11: 1739-1748, 2001.
28. Benz, C. C., O'Hagan, R. C., Richter, B., Scott, G. K., Chang, C. H., Xiong, X., Chew, K., Ljung, B. M., Edgerton, S., Thor, A., et al. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene, 15: 1513-1525, 1997.
29. Rosner, A., Miyoshi, K., Landesman-Bollag, E., Xu, X., Seldin, D. C., Moser, A. R., MacLeod, C. L., Shyamala, G., Gillgrass, A. E., and Cardiff, R. D. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am. J. Pathol., 161: 1087-1097, 2002.
30. Desai, K. V., Xiao, N., Wang, W., Gangi, L., Greene, J., Powell, J. I., Dickson, R., Furth, P., Hunter, K., Kucherlapati, R., et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc. Natl. Acad. Sci. USA, 99: 6967-6972, 2002.
31. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. Molecular portraits of human breast tumours. Nature, 406: 747-752, 2000.
32. Kauraniemi, P., Barlund, M., Monni, O., and Kallioniemi, A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res., 61: 8235-8240. 2001.
33. Varis, A., Wolf, M., Monni, O., Vakkari, M. L., Kokkola, A., Moskaluk, C., Frierson, H., Jr., Powell, S. M., Knuutila, S., Kallioniemi, A., et al. Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res., 62: 2625-2629, 2002.
34. Zhang, M., Liu, P., Dwyer, N. K., Christenson, L. K., Fujimoto, T., Martinez, F., Comly, M., Hanover, J. A., Blanchette-Mackie, E. J., and Strauss, J. F., III. MLN64 mediates mobilization of lysosomal cholesterol to steroidogenic mitochondria. J. Biol. Chem., 277: 33300-33310, 2002.
35. Sweeney, C., Fambrough, D., Huard, C., Diamonti, A. J., Lander, E. S., Cantley, L. C., and Carraway, K. L., III. Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. J. Biol. Chem., 276: 22685-22698, 2001.
36. Andrechek, E. R., Hardy, W. R., Girgis-Gabardo, A. A., Perry, R. L., Butler, R., Graham, F. L., Kahn, R. C., Rudnicki, M. A., and Muller, W. J. ErbB2 is required for muscle spindle and myoblast cell survival. Mol. Cell. Biol., 22: 4714-4722, 2002.
37. Tourtellotte, W. G., and Milbrandt, J. Sensory ataxia and muscle spindle agenesis in mice lacking the transcription factor Egr3. Nat. Genet., 20: 87-91, 1998.
38. Garratt, A. N., Voiculescu, O., Topilko, P., Chamay, P., and Birchmeier, C. A dual role of erbB2 in myelination and in expansion of the schwann cell precursor pool. J. Cell Biol., 148: 1035-1046, 2000.
39. Schneider-Maunoury, S., Topilko, P., Seitandou, T., Levi, G., Cohen-Tannoudji, M., Pournin, S., Babinet, C., and Charnay, P. Disruption of Krox-20 results in alteration of rhombomeres 3 and 5 in the developing hindbrain. Cell, 75: 1199-1214, 1993.
40. Voiculescu, O., Taillebourg, E., Pujades, C., Kress, C., Buart, S., Charnay, P., and Schneider-Maunoury, S. Hindbrain patterning: Krox20 couples segmentation and specification of regional identity. Development, 128: 4967-4978, 2001.
41. Jepson, S., Komatsu, M., Haq, B., Arango, M. E., Huang, D., Carraway, C. A., and Carraway, K. L. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways. Oncogene, 21: 7524-7532, 2002.
42. Schwidetzky, U., Schleuning, W. D., and Haendler, B. Isolation and characterization of the androgen-dependent mouse cysteine-rich secretory protein-1 (CRISP-1) gene. Biochem. J., 321: 325-332, 1997.
43. Li, Y., Ren J., Yu, W., Li, Q., Kuwahara, H., Yin, L., Carraway, K. L., III, and Kufe, D. The epidermal growth factor receptor regulates interaction of the human DF3/MUCI carcinoma antigen with c-Src and beta-catenin. J. Biol. Chem., 276: 35239-35242, 2001.